These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32546047)

  • 1. Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic.
    Qian K; Hu S
    MAbs; 2020; 12(1):e1782600. PubMed ID: 32546047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.
    Ryan PM; Caplice N
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532804
    [No Abstract]   [Full Text] [Related]  

  • 3. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
    Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.
    Braga CL; Silva-Aguiar RP; Battaglini D; Peruchetti DB; Robba C; Pelosi P; Rocco PRM; Caruso-Neves C; Silva PL
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00623. PubMed ID: 32658389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
    Lores E; Wysocki J; Batlle D
    Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H
    Yang G
    Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
    Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
    Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
    Nicolau LAD; Nolêto IRSG; Medeiros JVR
    Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
    [No Abstract]   [Full Text] [Related]  

  • 9. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
    Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
    Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.
    Ahlawat S; Asha ; Sharma KK
    Virus Res; 2020 Sep; 286():198103. PubMed ID: 32717345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin therapy and SAR-COV-2: an available and potential therapy?
    Abdel-Latif RG; Mohammed S; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
    [No Abstract]   [Full Text] [Related]  

  • 12. Sofosbuvir for COVID-19 infection: A potential candidate.
    Gupta R; Dhamija P
    Indian J Pharmacol; 2020; 52(3):232-233. PubMed ID: 32874010
    [No Abstract]   [Full Text] [Related]  

  • 13. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the type of diabetes treatment relevant to outcome of COVID-19?
    Bloomgarden Z
    J Diabetes; 2020 Jul; 12(7):486-487. PubMed ID: 32353193
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
    Roshanravan N; Ghaffari S; Hedayati M
    Diabetes Metab Syndr; 2020; 14(4):637-639. PubMed ID: 32428864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
    Sinha S; Sehgal A; Sehgal R
    Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins in coronavirus outbreak: It's time for experimental and clinical studies.
    Bifulco M; Gazzerro P
    Pharmacol Res; 2020 Jun; 156():104803. PubMed ID: 32289478
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.